IGC Provides Update On Phytocannabinoid IP Portfolio

BETHESDA, Md., Nov. 02, 2016 (GLOBE NEWSWIRE) -- India Globalization Capital, Inc. (NYSE MKT:IGC) announces updates for five patents related to method and treatment of pain, seizures and eating disorders utilizing a combination of Phytocannabinoid Cannabidiol (CBD) and other compounds.                                   
Indication  Provisional Filing    PCT Filing  Subsequent Activity
Pain (Case 1) 9/16/14 9/16/15 US National Case Filed - 6/15/16
Seizures (Case 2) 6/15/15 6/14/16 US National Case Filed - 6/15/16
Seizures (Case 3) 4/1/15 4/1/16 PCT Application Published- 10/6/16
Eating Disorders (Case 4)   8/12/15 8/11/16 US and National Filing Anticipated 2/12/18
Seizures (Case 5) 6/15/16 Anticipated- 6/15/17   US and National Filing Anticipated 12/15/18

Phytocannabinoids are chemical compounds that exert a range of effects on the human body, including impacting the immune response, gastrointestinal maintenance and motility, muscle functioning, and nervous system response and functioning. We have filed five provisional patents with the United States Patent and Trademark Office ("USPTO"), in the combination therapy space, for the indications of Pain, Medical Refractory Epilepsy and Cachexia as part of our intellectual property strategy focused on the phytocannabinoid based health care industry. The above table summarizes the latest corporate activities and it should be noted that there is no guarantee that filing a provisional or a non-provisional patent application will result in a successful registration with the USPTO.

If you liked this article you might like

3 Stocks Pushing The Metals & Mining Industry Lower

3 Stocks Pushing The Basic Materials Sector Lower

3 Stocks Pushing The Materials & Construction Industry Lower

3 Stocks Pushing The Industrial Goods Sector Lower

3 Stocks Pushing The Industrial Goods Sector Lower